Objectives: Phosphorylated extracellular signal-regulated kinase (ERK) activates cell survival pathways and may promote tumor cell proliferation. The purpose of this study was to determine the level of phospho-ERK staining in pretreatment specimens, and the effect of a short course of radiation therapy (RT) on the levels of phospho-ERK in specimens of colorectal cancer. Methods: Specimens of colorectal tumors were obtained from patients beginning RT before surgery. Tumors were graded and histologically staged. Subsequently, tumor samples were reacted with antiphospho-ERK antibodies and the level of staining intensity was assessed. Results: Of the 12 subjects evaluated, 7 of 12 had tumors that positively stained for phospho-ERK before and/or after RT. Most patients who were phospho-ERK positive before RT converted to ERK negativity after RT.
1
The MEK/ERK cascade has been tied to oncogenic transformation and cancer progression. 2 Constitutive activation of MEK has been shown to bring about cellular transformation, whereas dominant negative MEKs reverse this process. 3 The MEK/ERK pathway has been demonstrated to be constitutively activated in a large number of tumor cell lines and primary human tumors. 4 However, few investigators have attempted to identify the role of this pathway in the pathophysiology of colorectal cancer. Several contemporary studies have shown that ERK may be important for colon cancer progression. Phorbol-ester-induced scattering of HT29-M6 colon cancer cells (a model of cancer progression) is mediated by ERK1/2 and prevented by the MEK inhibitor, PD 98059. 5 RAS-activating mutations occur in a majority of colorectal carcinomas, and RAS has been shown to induce proliferative pathways by activating ERK in DLD colon cancer cells. 6 In the DLD colon cancer line, proline oxidase (POX) over-expression induced apoptosis, which was associated with lower levels of phosphorylated ERK, suggesting that activated ERK has an antiapoptotic effect in colon cancer. 7 Colorectal cancer remains the third most common malignancy in the United States after tumors of the skin and lung. 8 The cornerstone of treatment for rectal cancer continues to be surgery; however, locally advanced cases (eg, AJCC stages II and III) are known to benefit from adjuvant treatment (eg, chemotherapy, radiation therapy). The molecular pathways responsible for the transformation of colorectal cells are not well understood, and there is an ongoing search for the signal transduction pathway that is disrupted in colorectal carcinoma.
Recently, evidence has been presented by Zhu and colleagues implicating the MAPK pathway in the genesis of colorectal cancer. 9 The T-cell-originated protein kinase (TOPK) is a MAPK kinase (MEK) oncogene that can constitutively activate the MAPK signal transduction pathway leading to increased levels of phospho-ERK and cellular transformation. In human colorectal cancer cell line HT116, knockdown of TOPK by siRNA reduces the rate of both in vitro and in vivo cell proliferation. In the aforementioned study, TOPK was found to phosphorylate ERK2, and phosph-ERK2 phosphorylates TOPK (positive feedback loop). This feedback loop can be blocked by knockdown of ERK2 using siRNA. 9 This raises the possibility that the level of phospho-ERK expression can be both a target and marker in colorectal cancer.
The aim of the present pilot study was to extend the findings of Zhu et al by determining whether colorectal tumor specimens positively stain for phospho-ERK. We also evaluated the impact of radiation therapy on MEK/ERK signaling among a relatively homogenous group of patients in terms of site (low-lying rectal carcinoma), stage (T3-4), and treatment scheme. The results of our study suggest that phospho-ERK staining is detected in more than half of the subjects studied, and that radiation induces changes in the expression of phospho-ERK even after a relatively brief period of time. Our data suggest that the intensity of phospho-ERK staining, if it correlates with tumor progression and outcome, may be a useful prognostic marker in colorectal cancer.
MATERIALS AND METHODS
The study was conducted at the Tel Aviv Sourasky Medical Center (TASMC). Between May 1996 and June 1999, TASMC established a policy of preoperative radiotherapy for resectable rectal cancer following the publication of the second Swedish Rectal Cancer Trial (Stockholm II). 10 The protocol required obtaining tissue samples before and after radiation treatment. Thus, it was possible to determine the effect of therapy on the MEK/ERK pathway on pathologic specimens of colon cancer after site-directed irradiation.
Ultrasonography was used for preoperative staging. As part of the protocol, patients underwent a pretreatment biopsy of the tumor, and during surgery, specimens of resected tumor were stored for future studies. To be included in the study, subjects had to have a primary, histologically proven, low-lying rectal cancer without metastatic spread. Before initiating this retrospective study, approval was obtained by the Helsinki Committee (eg, Institutional Review Board) of the TASMC as a discarded tissue protocol.
Once a diagnosis of adenocarcinoma of the rectum was established by biopsy, patients received an abbreviated course of pelvic irradiation one week before scheduled anterior resection or abdominoperineal excision of the tumor. On the basis of the protocol, patients received 25 Gy in 5 fractions with megavoltage photons. The clinical target volume included the primary tumor, the mesorectal and presacral lymph nodes, the lymph nodes along the internal iliac vessel, the lumbar lymph nodes up to the level of the 5th lumbar vertebral body, and the lymph nodes at the obturator foramina. Patients were treated in the prone position with a 3-field technique. Shielding of tissues that were not considered to be at risk for tumor dissemination was achieved with customized cerrobend blocks.
The diagnostic material from the biopsy was evaluated with hematoxylin and eosin staining, and specimens were graded and histologically typed (eg, mucinous vs. adenocarcinoma, etc). Resected specimens were examined by the study pathologist and reviewed by a senior pathologist both of whom were blinded to the clinical data. Each specimen was classified according to the staging system of the AJCC. Representative samples from either the pretreatment biopsy or the surgical specimens were immunostained with antibodies to phosphorylated ERK (cat No. M8159, Sigma Co., St. Louis, MO). This was done by standard cytohistochemical staining in the Department of Pathology at TASMC. A qualitative 4-point scale was developed to classify the intensity of staining based on the numbers of cells positive for phospho-ERK staining (negative, weakly positive, moderately positive, and strongly positive). In addition, the examining pathologist noted whether the staining was diffuse, primarily nuclear, or cytoplasmic. An example of phospho-ERK staining is displayed in Figure 1 .
RESULTS
Specimens of low-lying rectal carcinoma were obtained from 12 patients before radiotherapy treatment and during FIGURE 1. Changes in phospo-ERK staining in response to radiation treatment of colorectal cancer. Representative samples from the pretreatment biopsy and the surgical specimens were subjected to standard histochemical procedures for paraffin embedding and immunohistochemical analyses using mouse anti phospho-ERK Ab, relevant biotynilated 2nd Ab and routine detection. In this example, positive immunostaining was markedly reduced by the radiation therapy.
Corn et al
surgery. Table 1 lists the histologic characteristics of the tumor, and the AJCC staging before and after radiotherapy. The AJCC stage in 7 subjects did not change, 2 advanced from T2 to T3, and 3 regressed with 1 subject having complete eradication of the tumor. Samples were immunostained for phospho-ERK before initiation of radiation treatment and after completion of radiotherapy (ie, during the definitive surgical procedure). An example for the intensity of phospho-ERK staining before and after radiation therapy for 2 of the patients is shown in Figure 1 . The summary of these parameters is also listed in Table 1 . For 7 of the 12 subjects, there was positive phospho-ERK staining before and after radiation therapy. In 1 case (patient 5), a preirradiation biopsy could not be evaluated for phosphorylated ERK staining because the material had been exhausted during the initial histologic evaluation. In another case (patient 4), a complete pathologic response was achieved after the delivery of preoperative radiotherapy thereby precluding determination of phospho-ERK status in the operative specimen. Of the 10 remaining patients, 5 patients who were positive for phospho-ERK converted to a reduced signal (4 of 5 completely negative signal) after radiation therapy. Only 1 patient advanced from phospho-ERK negativity to a weak signal. In 4 subjects, no phospho-ERK signal was detected either before or after radiotherapy. In terms of the cellular location of phosphor-ERK, the intensity of the stain was greater in the nucleus reflective of the fact that ERK is most active in the nucleus. Staining was more intense in the case of the poorly differentiated carcinoma when compared with the moderately and well differentiated sample.
Tumors that manifested positive nuclear staining for ERK tended to be higher grade (mucinous, grade 3, grade 2). No grade 1 specimen stained positively for phosphorylated ERK. Conversely, tumors that were negative for phosphorylated ERK staining tended to be from the well-differentiated end of the spectrum (grade 1, grade 1-2, grade 2). No grade 3 specimen had negative phospho-ERK status.
Among the patients studied, no correlative patterns were identified between AJCC stage and the staining for phosphorylated ERK. As for the staining with anti-ERK antibodies not specific for phospho-ERK, our results indicate no significant differences in the amount of ERK between the different patients irrespective of the stage of the cancer or the treatment.
DISCUSSION
Recent studies involving colorectal cancer cell lines and specimens have shown that MEK/ERK signal transduction pathway has a critical role in the invasiveness and proliferative properties of these tumors. 9 On the basis of these findings, we undertook to retrospectively review colorectal tumor specimens to determine whether these tumors have significant levels of phosphorylated ERK (activated), and whether irradiation of the tumor site has an effect on the level of phospho-ERK staining. Our results show more than half of the tumor specimens stained positively for phospho-ERK, and in 5 of the 12 cases, treatment with radiation therapy resulted in a conversion from positive to negative phospho-ERK staining.
Various tyrosine kinase cascades have been implicated in tumorogenesis and even as predictors of histopathological damage resulting from radiation therapy. For instance, Yeoh and colleagues 11 have demonstrated that part of the chain of injurious events in irradiated colorectal tissue occurs as a result of the direct activation by ionizing radiation of NFKB. NFKB is another signaling factor that is often activated together with ERK, and it is therefore possible that similar behavior to that of NFKB holds true for the ERK cascade.
The recent study by Zhu et al underscores the importance of ERK. 9 TOPK, a putative oncogene that may be responsible for transformation in colorectal cancer phosphorylates ERK2, and ERK2 activates TOPK. The preliminary data from the present study indicate that radiation therapy has an effect on the levels of phospho-ERK, and the effect on phospho-ERK may be related to the beneficial effects of radiation in this form of cancer. Alternatively, phospho-ERK may be a prognostic marker with lower levels reflecting a better response to radiation therapy and an improved prognosis.
From a different perspective, the reversion from positive to negative phospho-ERK staining may have clinical significance. In tumor cell lines, irradiation of the cells results in the activation of several cell survival cascades (mitogenic, proliferation) including the RAF-MEK-ERK pathway. 12 In certain cell lines, ERK along with other mediators defend cells against radiation induced cytotoxicity by increasing radioresistance. 13, 14 Other researchers have found that activation of ERK by irradiation increases clonogenic radiosensitivity. 15 It has been suggested that inhibition of ERK activation by specific MEK inhibitors such as PD98059 might enhance the effects of radiation therapy providing that the tumor is a type in which activated ERK induces radioresistance. 16 In the present study, in a majority of patients, radiation therapy resulted in a decrease in phospho-ERK levels, and this may correlate with a better outcome due to the inactivation of ERK mediated survival pathways. Recently, members of the Ras-MAPK cascade have emerged as attractive targets for pharmacologic intervention in cancer. For instance, CI-1040 became the first MEKtargeted agent to enter clinical trials and was found to be a highly potent and selective inhibitor of both MEK isoforms. 17 The drug was found to inhibit the clonogenic growth of a diverse panel of tumor cell lines including colorectal cancer. 18 Furthermore, a second generation oral MEK inhibitor (PD0325901) seems to be 50-fold more potent than CI-1040 while possessing improved bioavailability. 19 These observations are likely to spur the development of additional MEK inhibitors, especially those targeting TOPK, which may be instrumental in combating those tumors that seem to be resistant to radiation alone. Thus assessing the status of phospho-ERK at various stages may guide therapy.
This study was limited by the fact that there were no control specimens of normal colorectal tissue. However, our results were comparable to those of Zhu et al as 64% of the colorectal cancer specimens in our study were positive for phospho-ERK staining when compared with 81% of the specimens that were positive for TOPK staining. Although the present study was a retrospective study done in a limited number of patients, the increased levels of phospho-ERK seen initially in most patients, and the reduction in phospho-ERK in the majority of patients after a short course of radiation therapy would suggest that phospho-ERK could serve as an important surrogate marker in terms of response to therapy.
This study shows the feasibility of assessing phospho-ERK levels in tumor specimens and the potential utility of phospho-ERK as a prognostic indicator. Additional studies are necessary to determine which clinical and molecular factors relate to pretreatment phospho-ERK levels, and whether phospho-ERK levels are related to clinical outcome. In addition, it would be important to assess the levels of phospo-ERK and other signaling molecules in the MAPK pathway including TOPK in both colorectal cancer and normal colorectal tissue to determine which factors best correlate with phospho-ERK levels.
